Positive Outlook on Sana Biotechnology Driven by Promising T1D Program and Allogeneic CAR-T Advancements

Citi analyst Samantha Semenkow has maintained their bullish stance on SANA stock, giving a Buy rating on July 2.

Samantha Semenkow’s rating is based on a combination of factors that highlight Sana Biotechnology’s potential in addressing significant market opportunities. The company’s Type 1 Diabetes (T1D) program has shown promising proof-of-concept results, with updated six-month data demonstrating successful graft survival and durable c-peptide production without the need for immunosuppression. This consistency in data strengthens confidence in Sana’s approach and suggests a positive outlook for their T1D asset, SC451, which is expected to progress towards an IND as early as 2026.
Sana’s advancements in their allogeneic CAR-T platform also contribute to the Buy rating. The anticipated data readouts from their hypoimmune-modified allogeneic CAR-T assets, targeting autoimmune diseases and CD19-relapsed NHL, are expected to provide further insights into the platform’s potential. Additionally, Sana’s ownership of worldwide rights to their assets offers strategic financial leverage. These factors, combined with the expected high share price return, underpin Semenkow’s positive outlook on Sana Biotechnology.

Semenkow covers the Healthcare sector, focusing on stocks such as Argenx Se, Catalyst Pharma, and Larimar Therapeutics. According to TipRanks, Semenkow has an average return of -17.4% and a 26.00% success rate on recommended stocks.

In another report released on July 2, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $12.00 price target.